QXL-138AM is under clinical development by Nammi Therapeutics and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Metastatic Renal Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QXL-138AM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QXL-138AM overview
QXL-138AM is under development for the treatment of multiple myeloma, metastatic ovarian cancer, metastatic pancreatic cancer, metastatic urothelial cancer, metastatic renal cancer, metastatic hepatocellular cancer, metastatic gastrointestinal cancer, metastatic lung cancer, metastatic prostate cancer, metastatic breast cancer, bladder cancer, head and neck carcinoma, colon cancer, lung cancer, renal cancer. It acts by targeting IFNAR1, IFNAR2 and cells expressing CD138. The drug candidate is a anti-CD138 fused with Interferon (IFN) alpha. It is administered by intravenous route.
Nammi Therapeutics overview
Nammi Therapeutics (Nammi) is a immuno-oncology company developing products for the treatment of cancer. The company product portfolio includes QLX138AM, SLNP-IC1 and NTI-121. Nammi’s lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. The company also developed a nanoparticle platform to provide Immune Modulating Prodrugs (IMPs) using their Nammisome Technology. Nammi is headquartered in Los Angeles, California, the US.
For a complete picture of QXL-138AM’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
